Previous Close | 3.0900 |
Open | 3.1400 |
Bid | 3.0700 x 1800 |
Ask | 3.1800 x 1100 |
Day's Range | 3.0601 - 3.2000 |
52 Week Range | 2.9000 - 5.9900 |
Volume | |
Avg. Volume | 683,995 |
Market Cap | 953.068M |
Beta (5Y Monthly) | 1.21 |
PE Ratio (TTM) | 314.00 |
EPS (TTM) | 0.0100 |
Earnings Date | Nov 01, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AMRX
The recent 10% drop in Amneal Pharmaceuticals, Inc.'s ( NYSE:AMRX ) stock could come as a blow to insiders who...
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $559 million, an increase of 5% Y/Y, beating the consensus of $536.34 million. The increase was driven by growth across all three segments with solid broad-based performance in generics, including injectables. Adjusted EPS was $0.19, missed the consensus of $0.20, and was lower than the $0.23 posted a year ago. Adjusted EBITDA decreased 6% to $135 million, reflecting lower gross profit due to product mix and a tough comparison to the
Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?